TABLE 1.
Demographics and clinical characteristics of subjectsc
| Variable | Value for patient population (n = 34) |
|---|---|
| Median age (yrs) (range)a | 1.4 (0.03–14.6) |
| No. (%) of female subjects | 21 (61.8) |
| Median body wt (kg) (range)a | 8.9 (2.7–40.9) |
| Median ht (cm) (range)a | 142.5 (74.5–93.5) |
| Median serum creatinine concn (mg/dl) (range)a | 0.2 (0.1–5.5) |
| Median eGFR (ml/min) (range)a | 38.2 (1.4–183.8) |
| Median vol of diuresis (ml/kg/24 h) (range)a | 53.9 (0–323.9) |
| No. (%) of patients with ascitesa | 17 (50.0) |
| Median vol of ascites (ml/24 h) (range)a | 105 (0–9,000) |
| No. (%) of patients by SIRS scoreb | |
| 0 | 10 (29.4) |
| 1 | 7 (20.6) |
| 2 | 9 (26.5) |
| 3 | 7 (20.6) |
| 4 | 1 (2.9) |
| No. (%) of patients who received liver transplantation | 14 (41.1) |
| No. (%) of patients receiving: | |
| CRRT | 8 (23.5) |
| ECMO | 3 (8.8) |
| Vasopressors | 19 (55.9) |
| Median dialysate flow rate (ml/h) (range) | 1,600 (600–4,100) |
| Median filtrate flow rate (ml/h) (range) | 1,600 (600–8,400) |
| Median blood flow (ml/min) (range) | 40 (15–80) |
| Median time of MEM administration (days) (range) | 5 (1–16) |
| Median MEM dose (mg/kg/day) (range) | 105.2 (40.0–293.4) |
| Median MEM dose (mg/kg/dose) (range) | 36.4 (14.7–97.8) |
| No. (%) of patients receiving intravenous MEM by: | |
| Standard 1-h infusion | 27 (79.4) |
| Prolonged 3-h infusion | 9 (26.5) |
| No. (%) of patients with proven bacterial infection | 20 (58.8) |
| Median time to negative conversion of blood culture (h) (range) | 48 (24–120) |
| Median time to antipyretic response (days) (range) | 4 (0–23) |
| 30-day survival [no. (%) of patients] | 33 (97.1) |
| Serum samples analyzed for MEM concn (n = 290) | |
| No. (%) of scavenged samples | 256 (88.3) |
| No. (%) of prospective samples | 34 (11.7) |
| Median no. of samples per patient (range) | 9 (1–22) |
a
On the day of the study.
b
SIRS scores for each patient are indicated as the number of variables that met the SIRS criteria. The variables were provided as age-specific vital signs and laboratory variables (lower values for heart rate, leukocyte count, and systolic blood pressure). SIRS and CRRT were treated as categorical covariates. If the patient met ≥2 SIRS criteria for pediatric patients, the patient was categorized as SIRS+. If the patient was on continuous hemodialysis, the patient was categorized as CRRT+.
c
eGFR, estimated glomerular filtration rate; SIRS, systemic inflammatory response syndrome; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation.